Westfield Capital Management Co. LP Has $109.85 Million Stock Position in Insulet Corporation $PODD

Westfield Capital Management Co. LP boosted its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 91.9% during the 4th quarter, Holdings Channel reports. The institutional investor owned 386,468 shares of the medical instruments supplier’s stock after buying an additional 185,081 shares during the period. Westfield Capital Management Co. LP’s holdings in Insulet were worth $109,850,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Larson Financial Group LLC raised its position in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares during the period. Elyxium Wealth LLC acquired a new position in Insulet during the fourth quarter valued at $28,000. Fideuram Asset Management Ireland dac acquired a new position in Insulet during the fourth quarter valued at $41,000. Measured Wealth Private Client Group LLC acquired a new position in Insulet during the third quarter valued at $49,000. Finally, Osterweis Capital Management Inc. acquired a new position in Insulet during the second quarter valued at $51,000.

Insiders Place Their Bets

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was purchased at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.36% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have commented on PODD. Evercore lowered their target price on Insulet from $240.00 to $200.00 in a research note on Thursday, May 7th. William Blair began coverage on Insulet in a research note on Wednesday, May 20th. They issued an “outperform” rating on the stock. Piper Sandler lowered their target price on Insulet from $360.00 to $210.00 in a research note on Wednesday, May 6th. Leerink Partners lowered their target price on Insulet from $360.00 to $247.00 in a research note on Thursday, May 7th. Finally, Benchmark restated a “buy” rating on shares of Insulet in a research note on Wednesday, May 27th. Twenty-one investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $252.04.

Insulet Stock Performance

PODD opened at $146.41 on Friday. The company has a market cap of $10.14 billion, a PE ratio of 34.05, a price-to-earnings-growth ratio of 1.13 and a beta of 1.13. The stock has a 50-day moving average of $176.99 and a 200-day moving average of $239.50. Insulet Corporation has a 52-week low of $140.63 and a 52-week high of $354.88. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. During the same quarter in the prior year, the company posted $1.02 EPS. The firm’s revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities research analysts forecast that Insulet Corporation will post 6.44 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.